[FWP] Inverse VIX Short-Term Futures ETNs due March 22, 2045 Free Writing Prospectus
Denali Therapeutics Inc. (DNLI) filed a Form 144 indicating a planned insider sale of 495,282 common shares. The shares have an aggregate market value of approximately $7.10 million based on the broker’s data supplied in the filing. The proposed transaction will be executed through Jefferies LLC on or after 9 July 2025 on the NASDAQ exchange.
The shares were originally acquired on 21 August 2015 via a stock-option exercise. No sales by the same account holder were reported in the prior three-month period, and no non-cash consideration or special payment terms were disclosed. With 145 million shares outstanding, the planned sale represents roughly 0.34 % of total shares, suggesting limited dilution or float impact. No remarks, Rule 10b5-1 plan dates, or material adverse information were provided, and the filer attested to compliance with Rule 144 requirements.
Denali Therapeutics Inc. (DNLI) ha presentato un modulo Form 144 indicando una vendita interna pianificata di 495.282 azioni ordinarie. Le azioni hanno un valore di mercato complessivo di circa 7,10 milioni di dollari secondo i dati del broker forniti nella documentazione. La transazione proposta sarà eseguita tramite Jefferies LLC a partire dal 9 luglio 2025 sul mercato NASDAQ.
Le azioni sono state originariamente acquisite il 21 agosto 2015 tramite l'esercizio di un'opzione azionaria. Nessuna vendita da parte dello stesso detentore è stata segnalata nei tre mesi precedenti, e non sono state rivelate forme di pagamento non in contanti o condizioni particolari. Con 145 milioni di azioni in circolazione, la vendita pianificata rappresenta circa il 0,34% del totale delle azioni, suggerendo un impatto limitato su diluizione o flottante. Non sono stati forniti commenti, date di piani secondo la Regola 10b5-1 o informazioni materiali negative, e il dichiarante ha attestato la conformità ai requisiti della Regola 144.
Denali Therapeutics Inc. (DNLI) presentó un Formulario 144 indicando una venta interna planificada de 495,282 acciones comunes. Las acciones tienen un valor de mercado agregado de aproximadamente 7,10 millones de dólares según los datos del corredor proporcionados en la presentación. La transacción propuesta se ejecutará a través de Jefferies LLC a partir del 9 de julio de 2025 en la bolsa NASDAQ.
Las acciones fueron adquiridas originalmente el 21 de agosto de 2015 mediante el ejercicio de una opción sobre acciones. No se reportaron ventas por parte del mismo titular en los tres meses previos, ni se revelaron pagos en especie o términos especiales. Con 145 millones de acciones en circulación, la venta planificada representa aproximadamente el 0,34% del total de acciones, indicando un impacto limitado en la dilución o flotación. No se proporcionaron comentarios, fechas de planes bajo la Regla 10b5-1 ni información adversa material, y el declarante confirmó el cumplimiento de los requisitos de la Regla 144.
Denali Therapeutics Inc.(DNLI)는 495,282주의 보통주 내부자 매각 계획을 알리는 Form 144를 제출했습니다. 제출서류에 제공된 중개업체 데이터를 기준으로 해당 주식의 총 시장 가치는 약 710만 달러입니다. 제안된 거래는 2025년 7월 9일 이후 NASDAQ 거래소에서 Jefferies LLC를 통해 실행될 예정입니다.
해당 주식은 2015년 8월 21일 주식옵션 행사로 처음 취득되었습니다. 동일 계좌 보유자의 최근 3개월 내 매각 내역은 없으며, 현금 외 대가나 특별 지급 조건도 공개되지 않았습니다. 총 1억 4500만 주가 발행된 가운데, 이번 매각은 전체 주식의 약 0.34%에 해당해 희석 효과나 유동성에 미치는 영향이 제한적임을 시사합니다. 별도의 언급, Rule 10b5-1 계획 날짜, 중대한 악재 정보는 제공되지 않았으며, 신고자는 Rule 144 요건 준수를 확인했습니다.
Denali Therapeutics Inc. (DNLI) a déposé un formulaire 144 indiquant une vente d’initié prévue de 495 282 actions ordinaires. Les actions ont une valeur marchande totale d’environ 7,10 millions de dollars selon les données du courtier fournies dans le dépôt. La transaction proposée sera réalisée par l’intermédiaire de Jefferies LLC à partir du 9 juillet 2025 sur le marché NASDAQ.
Les actions ont été initialement acquises le 21 août 2015 par l’exercice d’une option d’achat d’actions. Aucune vente par le même détenteur de compte n’a été signalée au cours des trois derniers mois, et aucune contrepartie non monétaire ni condition de paiement spéciale n’a été divulguée. Avec 145 millions d’actions en circulation, la vente prévue représente environ 0,34 % du total des actions, ce qui suggère un impact limité sur la dilution ou la flottabilité. Aucune remarque, date de plan selon la règle 10b5-1 ou information défavorable importante n’a été fournie, et le déclarant a attesté du respect des exigences de la règle 144.
Denali Therapeutics Inc. (DNLI) hat ein Formular 144 eingereicht, das einen geplanten Insider-Verkauf von 495.282 Stammaktien anzeigt. Die Aktien haben einen Gesamtmarktwert von etwa 7,10 Millionen US-Dollar basierend auf den vom Broker bereitgestellten Daten in der Einreichung. Die vorgeschlagene Transaktion wird über Jefferies LLC am oder nach dem 9. Juli 2025 an der NASDAQ-Börse ausgeführt.
Die Aktien wurden ursprünglich am 21. August 2015 durch Ausübung einer Aktienoption erworben. Im vorangegangenen Dreimonatszeitraum wurden keine Verkäufe durch denselben Kontoinhaber gemeldet, und es wurden keine nicht-monetären Gegenleistungen oder Sonderzahlungsbedingungen offengelegt. Bei 145 Millionen ausstehenden Aktien stellt der geplante Verkauf etwa 0,34 % der Gesamtaktien dar, was auf eine begrenzte Verwässerung oder Auswirkung auf den Streubesitz hindeutet. Es wurden keine Bemerkungen, Daten von Rule-10b5-1-Plänen oder wesentliche negative Informationen bereitgestellt, und der Einreicher bestätigte die Einhaltung der Anforderungen von Rule 144.
- Small proportion: The 495,282 shares represent only about 0.34 % of DNLI’s outstanding shares, limiting dilution or supply shock.
- Regulatory compliance: Filing under Rule 144 with no reported non-cash consideration or adverse information indicates standard, transparent execution.
- Insider selling signal: Any insider-driven disposal can be perceived negatively, potentially hinting at reduced insider confidence even if routine.
Insights
TL;DR: Routine Form 144 for 495k DNLI shares (~0.34 % of SO); modest $7.1 m value, limited market impact.
The notice flags a forthcoming disposition by an insider or affiliate but, at 0.34 % of shares outstanding, the transaction is unlikely to materially pressure DNLI’s share price or signal fundamental weakness. The filing lacks information about the seller’s identity or motivation, and there are no concurrent sales in the past quarter. Investors typically monitor insider activity, yet this sale appears ordinary-course and within Rule 144 thresholds. Overall impact is neutral, though persistent insider selling could merit follow-up.
TL;DR: Insider sale disclosed; size small, regulatory clean, risk profile unchanged.
From a governance and compliance standpoint, the filer affirms no undisclosed adverse information and has not used non-cash consideration, reducing fraud or conflict concerns. The absence of recent insider sales suggests this is not part of a broader liquidation trend. However, insider sales occasionally precede negative catalysts, so traders may interpret the filing cautiously. Given scale and transparency, I classify the event as non-impactful.
Denali Therapeutics Inc. (DNLI) ha presentato un modulo Form 144 indicando una vendita interna pianificata di 495.282 azioni ordinarie. Le azioni hanno un valore di mercato complessivo di circa 7,10 milioni di dollari secondo i dati del broker forniti nella documentazione. La transazione proposta sarà eseguita tramite Jefferies LLC a partire dal 9 luglio 2025 sul mercato NASDAQ.
Le azioni sono state originariamente acquisite il 21 agosto 2015 tramite l'esercizio di un'opzione azionaria. Nessuna vendita da parte dello stesso detentore è stata segnalata nei tre mesi precedenti, e non sono state rivelate forme di pagamento non in contanti o condizioni particolari. Con 145 milioni di azioni in circolazione, la vendita pianificata rappresenta circa il 0,34% del totale delle azioni, suggerendo un impatto limitato su diluizione o flottante. Non sono stati forniti commenti, date di piani secondo la Regola 10b5-1 o informazioni materiali negative, e il dichiarante ha attestato la conformità ai requisiti della Regola 144.
Denali Therapeutics Inc. (DNLI) presentó un Formulario 144 indicando una venta interna planificada de 495,282 acciones comunes. Las acciones tienen un valor de mercado agregado de aproximadamente 7,10 millones de dólares según los datos del corredor proporcionados en la presentación. La transacción propuesta se ejecutará a través de Jefferies LLC a partir del 9 de julio de 2025 en la bolsa NASDAQ.
Las acciones fueron adquiridas originalmente el 21 de agosto de 2015 mediante el ejercicio de una opción sobre acciones. No se reportaron ventas por parte del mismo titular en los tres meses previos, ni se revelaron pagos en especie o términos especiales. Con 145 millones de acciones en circulación, la venta planificada representa aproximadamente el 0,34% del total de acciones, indicando un impacto limitado en la dilución o flotación. No se proporcionaron comentarios, fechas de planes bajo la Regla 10b5-1 ni información adversa material, y el declarante confirmó el cumplimiento de los requisitos de la Regla 144.
Denali Therapeutics Inc.(DNLI)는 495,282주의 보통주 내부자 매각 계획을 알리는 Form 144를 제출했습니다. 제출서류에 제공된 중개업체 데이터를 기준으로 해당 주식의 총 시장 가치는 약 710만 달러입니다. 제안된 거래는 2025년 7월 9일 이후 NASDAQ 거래소에서 Jefferies LLC를 통해 실행될 예정입니다.
해당 주식은 2015년 8월 21일 주식옵션 행사로 처음 취득되었습니다. 동일 계좌 보유자의 최근 3개월 내 매각 내역은 없으며, 현금 외 대가나 특별 지급 조건도 공개되지 않았습니다. 총 1억 4500만 주가 발행된 가운데, 이번 매각은 전체 주식의 약 0.34%에 해당해 희석 효과나 유동성에 미치는 영향이 제한적임을 시사합니다. 별도의 언급, Rule 10b5-1 계획 날짜, 중대한 악재 정보는 제공되지 않았으며, 신고자는 Rule 144 요건 준수를 확인했습니다.
Denali Therapeutics Inc. (DNLI) a déposé un formulaire 144 indiquant une vente d’initié prévue de 495 282 actions ordinaires. Les actions ont une valeur marchande totale d’environ 7,10 millions de dollars selon les données du courtier fournies dans le dépôt. La transaction proposée sera réalisée par l’intermédiaire de Jefferies LLC à partir du 9 juillet 2025 sur le marché NASDAQ.
Les actions ont été initialement acquises le 21 août 2015 par l’exercice d’une option d’achat d’actions. Aucune vente par le même détenteur de compte n’a été signalée au cours des trois derniers mois, et aucune contrepartie non monétaire ni condition de paiement spéciale n’a été divulguée. Avec 145 millions d’actions en circulation, la vente prévue représente environ 0,34 % du total des actions, ce qui suggère un impact limité sur la dilution ou la flottabilité. Aucune remarque, date de plan selon la règle 10b5-1 ou information défavorable importante n’a été fournie, et le déclarant a attesté du respect des exigences de la règle 144.
Denali Therapeutics Inc. (DNLI) hat ein Formular 144 eingereicht, das einen geplanten Insider-Verkauf von 495.282 Stammaktien anzeigt. Die Aktien haben einen Gesamtmarktwert von etwa 7,10 Millionen US-Dollar basierend auf den vom Broker bereitgestellten Daten in der Einreichung. Die vorgeschlagene Transaktion wird über Jefferies LLC am oder nach dem 9. Juli 2025 an der NASDAQ-Börse ausgeführt.
Die Aktien wurden ursprünglich am 21. August 2015 durch Ausübung einer Aktienoption erworben. Im vorangegangenen Dreimonatszeitraum wurden keine Verkäufe durch denselben Kontoinhaber gemeldet, und es wurden keine nicht-monetären Gegenleistungen oder Sonderzahlungsbedingungen offengelegt. Bei 145 Millionen ausstehenden Aktien stellt der geplante Verkauf etwa 0,34 % der Gesamtaktien dar, was auf eine begrenzte Verwässerung oder Auswirkung auf den Streubesitz hindeutet. Es wurden keine Bemerkungen, Daten von Rule-10b5-1-Plänen oder wesentliche negative Informationen bereitgestellt, und der Einreicher bestätigte die Einhaltung der Anforderungen von Rule 144.
The following is a summary of the terms of the notes offered by the preliminary pricing supplement hyperlinked below. Summary of Terms Issuer: JPMorgan Chase Financial Company LLC Guarantor: JPMorgan Chase & Co. Minimum Denomination: $1,000 Indices: S&P 500 ® Index and Russell 2000 ® Index Pricing Date: July 25, 2025 Observation Date: July 25, 2029 Maturity Date: July 30, 2029 Contingent Digital Return: At least 45.20 %* Barrier Amount: With respect to each Index, 75.00% of its Initial Value Payment at Maturity: If the Final Value of each Index is greater than or equal to its Initial Value, your payment at maturity per $1,000 principal amount note will be calculated as follows: $1,000 + ($1,000 î greater of (a) Contingent Digital Return and (b) Lesser Performing Index Return) If the Final Value of either Index is less than its Initial Value but the Final Value of each Index is greater than or equal to its Barrier Amount, you will receive the principal amount of your notes at maturity. If the Final Value of either Index is less than its Barrier Amount, your payment at maturity per $1,000 principal amount note will be calculated as follows: $1,000 + $1,000 x (Lesser Performing Index Return) If the Final Value of either Index is less than its Barrier Amount, you will lose more than 25.00% of your principal amount at maturity and could lose all of your principal amount at maturity. CUSIP: 48136FNM0 Preliminary Pricing Supplement: http://sp.jpmorgan.com/document/cusip/48136FNM0/doctype/Product_Termsheet/document.pdf Estimated Value: The estimated value of the notes, when the terms of the notes are set, will not be less than $900.00 per $1,000 principal amount note. For information about the estimated value of the notes, which likely will be lower than the price you paid for the notes, please see the hyperlink above. Any payment on the notes is subject to the credit risk of JPMorgan Chase Financial Company LLC, as issuer of the notes, and t he credit risk of JPMorgan Chase & Co., as guarantor of the notes. * The actual Contingent Digital Return will be provided in the pricing supplement and will not be less than 45.20%. ** Reflects a Contingent Digital Return equal to the minimum Contingent Digital Return set forth herein for illustrative purp ose s. The “total return” as used above is the number, expressed as a percentage, that results from comparing the payment at maturit y p er $1,000 principal amount note to $1,000. The hypothetical returns shown above apply only at maturity. These hypotheticals do not reflect fees or expenses that would b e a ssociated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns shown above would l ike ly be lower. Capitalized terms used but not defined herein shall have the meanings set forth in the preliminary pricing supplement. J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com Total Return on the Notes Lesser Performing Index Return Final Value of Lesser Performing Index 80.00% 80.00% 180.00 65.00% 65.00% 165.00 50.00% 50.00% 150.00 45.20% 45.20% 145.20 45.20% 40.00% 140.00 45.20% 30.00% 130.00 45.20% 20.00% 120.00 45.20% 10.00% 110.00 45.20% 5.00% 105.00 45.20% 0.00% 100.00 0.00% - 5.00% 95.00 0.00% - 10.00% 90.00 0.00% - 20.00% 80.00 0.00% - 25.00% 75.00 - 25.01% - 25.01% 74.99 - 30.00% - 30.00% 70.00 - 40.00% - 40.00% 60.00 - 60.00% - 60.00% 40.00 - 80.00% - 80.00% 20.00 - 100.00% - 100.00% 0.00 4y SPX/RTY Uncapped Digital Barrier Notes North America Structured Investments Hypothetical Total Returns**
J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com Selected Risks • Your investment in the notes may result in a loss. The notes do not guarantee any return of principal. • Your ability to receive the Contingent Digital Return may terminate on the Observation Date. • Any payment on the notes is subject to the credit risks of JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. Therefore the value of the notes prior to maturity will be subject to changes in the market’s view of the creditworthiness of JPMorgan Chase Financial Company LLC or JPMorgan Chase & Co. • You are exposed to the risk of decline in the level of each Index. • Your payment at maturity will be determined by the Lesser Performing Index. • The benefit provided by the Barrier Amount may terminate on the Observation Date. • No interest payments, dividend payments or voting rights. • JPMorgan Chase & Co. is currently one of the companies that make up the S&P 500 ® Index. • The notes are subject to the risks associated with small capitalization stocks with respect to the Russell 2000 ® Index. • As a finance subsidiary, JPMorgan Chase Financial Company LLC has no independent operations and has limited assets. Selected Risks (continued) • The estimated value of the notes will be lower than the original issue price (price to public) of the notes. • The estimated value of the notes is determined by reference to an internal funding rate. • The estimated value of the notes does not represent future values and may differ from others’ estimates. • The value of the notes, which may be reflected in customer account statements, may be higher than the then current estimated value of the notes for a limited time period. • Lack of liquidity: J.P. Morgan Securities LLC (who we refer to as JPMS) intends to offer to purchase the notes in the secondary market but is not required to do so. The price, if any, at which JPMS will be willing to purchase notes from you in the secondary market, if at all, may result in a significant loss of your principal. • Potential conflicts: We and our affiliates play a variety of roles in connection with the issuance of notes, including acting as calculation agent and hedging our obligations under the notes, and making the assumptions used to determine the pricing of the notes and the estimated value of the notes when the terms of the notes are set. It is possible that such hedging or other trading activities of J.P. Morgan or its affiliates could result in substantial returns for J.P. Morgan and its affiliates while the value of the notes declines. • The tax consequences of the notes may be uncertain. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes. Additional Information SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a pr osp ectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPM organ Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get the se documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participat ing in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement, underlying supplement and preliminary pricing supplement if you so request by c all ing toll - free 1 - 866 - 535 - 9248. IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion o f U .S. tax matters contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Cha se & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax - related penalties. Investment suitability must be determined individually for each investor, and the financial instruments described herein may not be suitable for all investors. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisers as to the se matters. This material is not a product of J.P. Morgan Research Departments Free Writing Prospectus Filed Pursuant to Rule 433, Registration Statement Nos. 333 - 270004 and 333 - 270004 - 01 North America Structured Investments 4y SPX/RTY Uncapped Digital Barrier Notes The risks identified above are not exhaustive. Please see “Risk Factors” in the prospectus supplement and the applicable prod uct supplement, Annex A to the prospectus addendum and “Selected Risk Considerations” in the applicable preliminary pricing supplement for additional information.
FAQ
How many Denali Therapeutics (DNLI) shares are being sold under this Form 144?
What is the market value of the DNLI shares listed for sale?
When is the approximate sale date for the DNLI shares?
What percentage of Denali Therapeutics’ shares outstanding does the sale represent?
Which broker is handling the proposed DNLI share sale?
How were the DNLI shares originally acquired?
